Compare Cadila Healthcare with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs GLENMARK PHARMA - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE GLENMARK PHARMA CADILA HEALTHCARE/
GLENMARK PHARMA
 
P/E (TTM) x 14.4 10.6 136.6% View Chart
P/BV x 2.8 1.5 186.5% View Chart
Dividend Yield % 1.5 0.7 218.2%  

Financials

 CADILA HEALTHCARE   GLENMARK PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
GLENMARK PHARMA
Mar-19
CADILA HEALTHCARE/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs558712 78.4%   
Low Rs362484 74.8%   
Sales per share (Unadj.) Rs116.3349.6 33.3%  
Earnings per share (Unadj.) Rs17.932.8 54.5%  
Cash flow per share (Unadj.) Rs23.144.3 52.2%  
Dividends per share (Unadj.) Rs3.502.00 175.0%  
Dividend yield (eoy) %0.80.3 227.5%  
Book value per share (Unadj.) Rs85.4198.6 43.0%  
Shares outstanding (eoy) m1,023.74282.17 362.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.01.7 231.3%   
Avg P/E ratio x25.718.2 141.1%  
P/CF ratio (eoy) x19.913.5 147.4%  
Price / Book Value ratio x5.43.0 178.9%  
Dividend payout %19.66.1 321.1%   
Avg Mkt Cap Rs m470,664168,625 279.1%   
No. of employees `00011.812.0 98.2%   
Total wages/salary Rs m18,54520,561 90.2%   
Avg. sales/employee Rs Th10,072.78,196.0 122.9%   
Avg. wages/employee Rs Th1,569.11,708.1 91.9%   
Avg. net profit/employee Rs Th1,547.7768.5 201.4%   
INCOME DATA
Net Sales Rs m119,04998,655 120.7%  
Other income Rs m1,1322,081 54.4%   
Total revenues Rs m120,181100,736 119.3%   
Gross profit Rs m28,47515,858 179.6%  
Depreciation Rs m5,3883,259 165.3%   
Interest Rs m9113,346 27.2%   
Profit before tax Rs m23,30811,335 205.6%   
Minority Interest Rs m6280-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m5,6443,756 150.3%   
Profit after tax Rs m18,2929,250 197.8%  
Gross profit margin %23.916.1 148.8%  
Effective tax rate %24.233.1 73.1%   
Net profit margin %15.49.4 163.9%  
BALANCE SHEET DATA
Current assets Rs m82,00566,968 122.5%   
Current liabilities Rs m60,72040,211 151.0%   
Net working cap to sales %17.927.1 65.9%  
Current ratio x1.41.7 81.1%  
Inventory Days Days7383 87.8%  
Debtors Days Days9881 121.1%  
Net fixed assets Rs m83,70333,322 251.2%   
Share capital Rs m1,024282 362.9%   
"Free" reserves Rs m86,42155,770 155.0%   
Net worth Rs m87,44556,052 156.0%   
Long term debt Rs m25,55135,738 71.5%   
Total assets Rs m180,653132,888 135.9%  
Interest coverage x26.64.4 605.9%   
Debt to equity ratio x0.30.6 45.8%  
Sales to assets ratio x0.70.7 88.8%   
Return on assets %10.69.5 112.1%  
Return on equity %20.916.5 126.8%  
Return on capital %22.017.8 123.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m42,68362,998 67.8%   
Fx outflow Rs m11,24222,859 49.2%   
Net fx Rs m31,44140,140 78.3%   
CASH FLOW
From Operations Rs m9,19313,242 69.4%  
From Investments Rs m-9,737-6,990 139.3%  
From Financial Activity Rs m515-7,387 -7.0%  
Net Cashflow Rs m-29-2,971 1.0%  

Share Holding

Indian Promoters % 74.8 48.3 154.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 6.9 120.3%  
FIIs % 5.9 34.4 17.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 10.5 104.8%  
Shareholders   44,069 56,727 77.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   CIPLA  PIRAMAL ENTERPRISES  NATCO PHARMA  SHASUN PHARMA  PFIZER  

Compare CADILA HEALTHCARE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Oct 18, 2019 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS